Ultimovacs has acquired the immunotherapy technology business of Immuneed AB for NOK 50 million.  The acquired business has been named Ultimovacs AB and is now a fully-owned Swedish subsidiary of Ultimovacs AS. The business is located in Uppsala and has two employees. “In Ultimovacs, we have been looking for an adjuvant technology that can further improve cancer vaccines. Simultaneously, Immuneed has been searching for a peptide based vaccine platform for further testing of their technolog...